Toxicities Associated with Immunotherapy and Approach to Cardiotoxicity with Novel Cancer Therapies

Cristina Gutierrez; Prabalini Rajendram; Stephen M. Pastores

doi:10.1016/j.ccc.2020.08.003

Toxicities Associated with Immunotherapy and Approach to Cardiotoxicity with Novel Cancer Therapies

Cristina Gutierrez, Prabalini Rajendram, Stephen M. Pastores

Critical Care & Respiratory Care

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

In recent years, major advances in oncology especially the advent of targeted agents and immunotherapies (immune checkpoint inhibitors [ICIs] and chimeric antigen receptor [CAR] T-cell therapy) have led to improved quality of life and survival rates in patients with cancer. This article focuses on the clinical features, and grading and management of toxicities associated with ICIs and CAR T-cell therapy. In addition, because cardiotoxicity is one of the most harmful effects of anticancer therapeutics, we describe the risk factors and mechanisms of cardiovascular injury associated with newer agents, screening technologies for at-risk patients, and preventive and treatment strategies.

Original language	English (US)
Pages (from-to)	47-67
Number of pages	21
Journal	Critical Care Clinics
Volume	37
Issue number	1
DOIs	https://doi.org/10.1016/j.ccc.2020.08.003
State	Published - Jan 2021

Keywords

Cardiotoxicity
Checkpoint inhibitors
Chimeric antigen receptor T-cell therapy
Critical illness
Cytokine release syndrome
Neurotoxicity
Oncology
Pneumonitis

ASJC Scopus subject areas

Critical Care and Intensive Care Medicine

Access to Document

10.1016/j.ccc.2020.08.003

Cite this

@article{7eb946849b9f479b9752744f38651e71,

title = "Toxicities Associated with Immunotherapy and Approach to Cardiotoxicity with Novel Cancer Therapies",

abstract = "In recent years, major advances in oncology especially the advent of targeted agents and immunotherapies (immune checkpoint inhibitors [ICIs] and chimeric antigen receptor [CAR] T-cell therapy) have led to improved quality of life and survival rates in patients with cancer. This article focuses on the clinical features, and grading and management of toxicities associated with ICIs and CAR T-cell therapy. In addition, because cardiotoxicity is one of the most harmful effects of anticancer therapeutics, we describe the risk factors and mechanisms of cardiovascular injury associated with newer agents, screening technologies for at-risk patients, and preventive and treatment strategies.",

keywords = "Cardiotoxicity, Checkpoint inhibitors, Chimeric antigen receptor T-cell therapy, Critical illness, Cytokine release syndrome, Neurotoxicity, Oncology, Pneumonitis",

author = "Cristina Gutierrez and Prabalini Rajendram and Pastores, {Stephen M.}",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2021",

month = jan,

doi = "10.1016/j.ccc.2020.08.003",

language = "English (US)",

volume = "37",

pages = "47--67",

journal = "Critical Care Clinics",

issn = "0749-0704",

publisher = "W.B. Saunders Ltd",

number = "1",

}

TY - JOUR

T1 - Toxicities Associated with Immunotherapy and Approach to Cardiotoxicity with Novel Cancer Therapies

AU - Gutierrez, Cristina

AU - Rajendram, Prabalini

AU - Pastores, Stephen M.

PY - 2021/1

Y1 - 2021/1

N2 - In recent years, major advances in oncology especially the advent of targeted agents and immunotherapies (immune checkpoint inhibitors [ICIs] and chimeric antigen receptor [CAR] T-cell therapy) have led to improved quality of life and survival rates in patients with cancer. This article focuses on the clinical features, and grading and management of toxicities associated with ICIs and CAR T-cell therapy. In addition, because cardiotoxicity is one of the most harmful effects of anticancer therapeutics, we describe the risk factors and mechanisms of cardiovascular injury associated with newer agents, screening technologies for at-risk patients, and preventive and treatment strategies.

AB - In recent years, major advances in oncology especially the advent of targeted agents and immunotherapies (immune checkpoint inhibitors [ICIs] and chimeric antigen receptor [CAR] T-cell therapy) have led to improved quality of life and survival rates in patients with cancer. This article focuses on the clinical features, and grading and management of toxicities associated with ICIs and CAR T-cell therapy. In addition, because cardiotoxicity is one of the most harmful effects of anticancer therapeutics, we describe the risk factors and mechanisms of cardiovascular injury associated with newer agents, screening technologies for at-risk patients, and preventive and treatment strategies.

KW - Cardiotoxicity

KW - Checkpoint inhibitors

KW - Chimeric antigen receptor T-cell therapy

KW - Critical illness

KW - Cytokine release syndrome

KW - Neurotoxicity

KW - Oncology

KW - Pneumonitis

UR - http://www.scopus.com/inward/record.url?scp=85094158805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85094158805&partnerID=8YFLogxK

U2 - 10.1016/j.ccc.2020.08.003

DO - 10.1016/j.ccc.2020.08.003

M3 - Review article

C2 - 33190775

AN - SCOPUS:85094158805

SN - 0749-0704

VL - 37

SP - 47

EP - 67

JO - Critical Care Clinics

JF - Critical Care Clinics

IS - 1

ER -

Toxicities Associated with Immunotherapy and Approach to Cardiotoxicity with Novel Cancer Therapies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this